Despite the curative potential of allogeneic stem cell transplantation (SCT), therapeutic options for patients relapsing after transplantation are limited and the prognosis is poor.
Unlike conventional therapeutic approaches, which employ agents that directly act on cancer cells, checkpoint blockade harnesses the immune system's inherent ability to eradicate cancer by fine-tuning physiological processes, that is, unleashing suppressed immune responses. 8 Our group and others have recently shown that PD-1 inhibition with nivolumab or pembrolizumab can also be effective and safe in the treatment of relapsed Hodgkin's disease or anaplastic large cell lymphoma (ALCL) after allogeneic SCT. [9] [10] [11] However, a case of fatal GvHD has been reported in a patient, who had received pembrolizumab, 12 indicating that life-threatening allo-immune responses can be provoked by targeting immune checkpoints. On the basis of the assumption that GvL effects might be compromised by PD-1 immune checkpoint activation, we treated three AML patients relapsing after allogeneic SCT and failing standard therapies with the anti-PD-1 blocking antibody nivolumab. All patients received nivolumab as compassionate use. Approval by the institutional review board was obtained before the experimental treatment was started.
PATIENT 1
The first patient is a 61-year-old male who was diagnosed with AML (normal karyotype). Following chemotherapy, the patient remained in CR for almost 3 years before being diagnosed with a relapse (Figure 1a ). After bridging chemotherapy and identification of an unrelated donor (10/10 HLA matched) allogeneic SCT was performed, resulting in a second CR with complete donor cell chimerism (DCC). Almost 6 months after allogeneic SCT a declining CD34 + DCC indicated an impending relapse (Figure 1b) . Immunosuppressive treatment consisting of cyclosporine A (CSA) was discontinued ( Figure 1a ). Despite treatment with DLI on days 195 and 223 after allogeneic SCT the patient progressed to overt AML with 20% blasts in the bone marrow by day 238. Nivolumab was administered as a single dose of 100 mg on day 244 after allogeneic SCT (Figure 1a) . Following administration of nivolumab, the patient developed marked pancytopenia (Figure 1c) , a known side effect of immune checkpoint blockade. 13 Two weeks later lymphocytes started to expand rapidly. Analysis of the cellular immune status revealed an expansion of CD19 + B and CD3 + T cells (Figure 1d ). Although the mixed DCC in the blood started to increase immediately, the
CD34
+ stem cell chimerism continued to drop to almost zero on day 14 following nivolumab. CD3 + T-cell infiltration of the bone marrow substantially increased within 4 weeks after nivolumab. This was associated with a significant reduction of AML bone marrow cellularity (Figure 1e ). The proportion of PD-1-positive CD8 + T cells declined to almost zero within the first 3 weeks following nivolumab administration (Figure 1g ). With delayed kinetics, a similar trend was noted for CTLA-4 (Figure 1g, right) . The same was true for PD-1-positive CD4 + T cells. Three weeks following nivolumab infusion, the patient developed skin GvHD (stage 3, grade 2 at maximum), which responded to topical treatment with corticosteroids and had completely resolved 30 days later (Figure 1a ). At the same time the DCC started to recover, first in the peripheral blood and then in bone marrow ( Figure 1b) . By day 294 the number of blasts in the bone marrow had declined to o 5%. By day 312 the CD34 + DCC had returned to 100% (Figure 1b ). Currently, 10 months after nivolumab administration the patient remains in CR without clinical signs of GvHD and a good performance status.
PATIENT 2
The second patient is a 44-year-old female, who was diagnosed with therapy-associated AML related to an adjuvant treatment of breast cancer 3 years earlier. Cytogenetics revealed a translocation t(9;11)(p22;q23) in all metaphases generating a leukemia-specific fusion gene product, MLL-AF9. MLL-AF9 mRNA was monitored throughout the course of disease using quantitative RT-PCR ( Figure 2f ). The patient was transplanted with a 9/10 HLA-matched unrelated donor in first CR, but relapsed 8 months later (Figures 2a and f). A second allogeneic SCT was performed in second CR using the same donor. This resulted in a complete molecular remission, but molecular relapse became evident more than 2 years later (Figures 2a and f) . DLI and low-dose interferon alpha failed to induce GvHD and to achieve leukemic control as evidenced by a steady increase in MLL-AF9 mRNA levels. With no signs of GvHD and an excellent performance status (ECOG 0), the patient was offered treatment with nivolumab. In order to avoid uncontrolled GvHD and in the absence of published experience, we chose a repetitive low-dose regimen of 0.3-1 mg nivolumab per kg body weight given weekly for a total of five infusions (Figure 2a) . Directly before the first nivolumab treatment, the patient was pancytopenic and severely hypocellular in the bone marrow with 6% leukemic blasts detected by flow cytometry (Figure 2d ). The MLL-AF9/ABL ratio was 3.192 and thus only one-log lower than at primary AML diagnosis. Nivolumab was discontinued after five weekly doses because of muscle and joint pain (WHO grade 2). After five nivolumab infusions the MLL-AF9 mRNA expression declined again by one-log, but molecular disease stabilization was noted since then (currently 6 months after treatment start). Intriguingly, treatment with nivolumab was associated with increasing numbers of CD8 + T cells and CD4 + T cells expressing the T-cell inhibitory receptor CTLA-4 and the T-cell activation marker PD-1 as representatively shown for the time point 70 days after first nivolumab treatment (Figures 2b,c and e) . 
PATIENT 3
The third patient is a 50-year-old white male, who was diagnosed with fms-related tyrosine kinase 3 internal tandem duplication-mutation positive AML. Following two cycles of chemotherapy the patient was transplanted with a 10/10 matched unrelated donor in first CR. Four months after allogeneic SCT the patient relapsed. A second allogeneic SCT was performed in CR using a different unrelated donor. Six months later a decline of the DCC in the CD34 + stem cell compartment was noted. DLI were not available. The patient was pancytopenic before nivolumab administration. Two injections of nivolumab (100 mg each) were given on days 157 and 171 after second allogeneic SCT. However, DCC continued to drop, cytopenia persisted, and the leukemia progressed. There was no objective response in this patient. Similar to what was observed in the second patient, in this third patient we also observed a precipitous increase of CTLA-4-expressing lymphocytes following administration of nivolumab. This patient then received a haploidentical transplant from the son, which was well tolerated, and remains in complete molecular remission 9 months later.
Here, we reported our experience regarding the efficacy and tolerability of an anti-PD-1 treatment with nivolumab in three AML patients who had relapsed after allogeneic SCT. One patient achieved an ongoing CR, one patient experienced disease stabilization and a third patient failed to respond to nivolumab. Interestingly, all patients showed an increase of CTLA-4-expressing lymphocytes, and after a transient drop directly after nivolumab treatment, numbers of PD-1-positive cells markedly increased in both responding patients, indicating a temporary loss of PD-1-mediated self-tolerance that might have allowed for GvL effects. The only side effects our patients experienced were immune-related pancytopenia and GvHD of the skin in one patient, as well as muscle and joint pain in another patient. Given the risk of detrimental GvHD we decided to administer low doses of nivolumab ranging from 0.3-1.5 mg per kg body weight, which appeared to be safe and well tolerated as none of our patients developed severe or even fatal GvHD. The optimal dose of nivolumab to restore GvL effects without causing severe GvHD remains to be determined, ideally within prospective trials. In summary, our report adds to the growing number of exciting reports demonstrating that checkpoint inhibition targeting PD-1 might be an effective and well-tolerated salvage therapy for relapsed hematological cancers after allogeneic SCT such as M Hodgkin, 9,10 ALCL 11 or AML and provides a rationale for further clinical investigation.
